Endotoxin for Late-Life Depression (SHARE-D Trial)

"This clinical trial is recruiting participants aged between 60 and 80 years of age."

"Yes, the records hosted on clinicaltrials.gov prove that this research is actively recruiting. The trial was initially made available to the public on January 1st 2018 and has since been revised a few times; most recently in September 30th 2022. This study requires 160 participants from one location for completion."

"This clinical trial, first posted on January 1st 2018, is currently enrolling volunteers. The most recent changes were made to the study information on September 30th 2022."

"This study is admitting 160 people aged between 60 and 80 who have melancholia. To be eligible, participants must demonstrate good overall health (confirmed during the phone and in-person baseline session). Additionally, half of these individuals should possess a diagnosis of insomnia disorder made through the Structured Clinical Interview for Diagnosis, Diagnostic Statistical Manual 5 or Duke Structured Interview for Sleep Disorders; while the other half will not have been identified as suffering from insomnia via any of those assessments."

"There is only a limited amount of data demonstrating the safety and efficacy of Endotoxin, so it was assigned a score 1 on our internal scale."

"This 12-hour study's primary goal is to evaluate the depressive mood of participants using the POMS. Secondary objectives include assessing patients' Hamilton Depression Rating Scale, Emotion Intensity Task (utilizing facial emotion recognition software), and Reward Learning Task which gauges an individual's behavior modification in response to rewards. A trained interviewer will be assigning ratings for depressed mood, guiltiness, loss of interest etc., while a computerized probabilistic reward task aids in measuring participant's ability to respond based on incentives received."